Aloperine Protects Mice against DSS-Induced Colitis by PP2A-Mediated PI3K/Akt/mTOR Signaling Suppression

Figure 3

Aloperine regulates T-cell proportions in spleens and mesenteric lymph nodes (MLNs) of DSS-induced colitis mouse model and in the spleens of the Foxp3^GFP mice. (a) Representative interleukin- (IL-) 17A, tumor growth factor- (TGF-) β, IL-10, forkhead box P3 (Foxp3) mRNA expressions, and IL-17A/Foxp3 ratio in the colon in each group. (b) Representative CD4⁺Foxp3⁺ T-cell frequencies in the spleens and MLNs in each group. (c, d) Mean fluorescence intensity (MFI) of CD44 in the spleens and MLNs in each group. (e) Representative CD4⁺Foxp3⁺ T-cell percentages in the spleens of the Foxp3^GFP mice. (f) MFI of CD62L in the spleens of the Foxp3^GFP mice. (g) Real-time PCR analysis of IL-17A, TGF-β, IL-10, Foxp3 mRNA expression, and IL-17A/Foxp3 ratio in mouse Tregs after a 24 h treatment with aloperine (0.25 mM). The data are presented as the mean ± SEM of 6 mice analyzed per group. , , and . ns: not significant.

(a)

(b)

(c)

(d)

(e)

(f)

(g)